Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegylated interferon plus tenofovir alafenamide stepwise therapy in HBeAg-positive chronic hepatitis B
ChiCTR2200056441Phase 4Not yet recruiting
- Sponsor
- Shanghai Public Health Clinical Center
- Start
- Jan 2022
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tenofovir alafenamide and pegylated interferon alpha in Chronic Hepatitis B (CHB) (3 arms), sponsored by Shanghai Public Health Clinical Center. Primary endpoint: HBeAg seroconversion rate. Planned start Jan 2022; status: not yet recruiting.
02
Drugs
tenofovir alafenamidepegylated interferon alpha
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ChiCTR2200056441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056441.